ROLE IN THE PROJECT
The general objective is to design an oral formulation of siRNA nanotherapeutics, able to locally deliver the JAK1/JAK3 siRNA to the inflamed colon.
This element could not render due to invalid template markup. This could be due to changes introduced by a third party plugin. The front end of your site should still function normally
Dr Fabrice Navarro, obtained his PhD in Molecular and Cell Biology, Physiology and Neurosciences in 2006 from University Claude Bernard of Lyon. After 2-years post-doctoral position at the CEA Tech on in vivo imaging by using nanoparticles, he obtained a permanent position as research scientist position at the CEA Tech for working on various nanomedecine projects.
Since 2012, he is currently principal investigator in collaborative projects dealing with the targeted delivery of bio-macromolecules, such as proteins, peptides and/or nucleic acids for applications ranging from the RNAi transfection to vaccine formulations. Since 2016, he is leading a laboratory of 16 permanent research scientists, engineers and technicians, dealing with the design and validation of new diagnostic tools or therapeutics strategies by using micro-and nano-technologies. Skills: Engineered nanoparticles, non-viral vectors, RNAi delivery, vaccine formulations, drug delivery, in vivo imaging, Cellular and animal models.
Xavier Gidrol received is PhD in Molecular and Cell Biology from Aix-Marseille University. He performed post-doctoral research at Harvard University (USA) and at the Institute of Molecular and Cell Biology (Singapore). He was specialized in transcriptional regulation of gene expression.
He got a tenure position at INRA France, and then served as Associate Director of R&D at Xenometrix Inc., a spin-off start-up from Harvard University, where he got interested in global approaches and genomics. He then joined in 2000 the newly created Functional Genomics Laboratory at France’s Atomic Energy Commission (CEA) in Paris and managed it until 2008. This laboratory focused on large scale functional genomics approaches to analyze proliferation/differentiation balance in oncology. In 2009, he was appointed director of a new laboratory, “Biomics” at CEA in Grenoble, to use microsystems for cell biology, where he focuses on large scale RNAi-based functional screening and 3D organoids oncology. Since 2015 he manages both the Biomics Laboratory and the “Large Scale Biology Unit” at CEA Grenoble. Xavier Gidrol authored or co-authored more than 110 publications.
ERS provides administrative support, helps to implement risk assessment, internal monitoring and common standard procedures, all in order to safeguard outcomes within time, budget and EU guidelines.
Oliver Panzer is stockholder and Managing Director of ERS. He holds a Diploma in physics, and worked 5 years as a postgraduate researcher in the area of nano-analytics. Next to experience in industry and in managing the office of a national network of excellence, he worked at the European Commission as a Seconded National Expert. His background will make sure that the management structure & procedures meet the needs of the European Commission.
In this project the HZI will contribute with its expert’s knowledge on advanced coculture models of the intestinal barrier and expertise in siRNA delivery.
Claus-Michael Lehr received his PhD from Leiden University. In 1991/92, he was a PostDoc in the lab of Prof. Vincent H. L. Lee, University of Southern California, USA, before he became 1992/93 a Research Associate at the Drug Research in Leiden, NL. In 1993, he was appointed full Professor for Pharmaceutical Technology at Philipps-University Marburg. Since 1995, he is full Professor and Head of Department Biopharmaceutics and Pharmaceutical Technology at Saarland University.
As one of the co-founders of the Helmholtz-Institute for Pharmaceutical Research Saarland (HIPS), Claus-Michael Lehr is head of the department “Drug Delivery” at the HIPS. He is also cofounder of Across Barriers GmbH and PharmBioTec GmbH, providing R&D services to the pharmaceutical industry.
NIT as WP5 leader will lead the “in vitro” and “in vivo” safety evaluation. Main contribution will be to study the safety and biocompatibility of the the products generated in the consortium.
Received his Ph.D in Biology from the University of Vigo, Spain. Associate professor of the University of Vigo, joins Nanoimmunotech as an expert in monoclonal antibodies development, as part of the technical department in 2012. Few years after, he becomes the manager of the Nitbiosafe department, being principal investigator of FP7 and H2020 projects. He is now the new Chief Innovation Officer at Nanoimmunotech. Senior researcher holds over 13 years of experience: in vitro and in vivo assays. His research activity is focused in the nano-biocompatibility, nanotoxicity, sterility and immunotoxicity evaluation.
IDIBAPS main goal is to translate basic discoveries into the clinics. To do so it brings together scientists with some of the top leaders in the world on diseases such as cancer, inflammation, immune mediated diseases, diabetes, infectious disease and neurological disorders, among others. As such IDIBAPS structure and purpose is aligned with the objectives of this proposal and provides the environment and infrastructure needed to perform in vivo studies and to potentially translate this into future clinical trials.
Dr. Salas has been devoted to biomedical science and in particular to the study of inflammatory mechanisms for over 20 years. She spent 5 years as a postdoctoral fellow at Harvard Medical School working on molecular mechanisms of integrin activation and mucosal immunology. Since November 2004 she has been an investigator at IDIBAPS, Hospital Clinic in Barcelona. She has served as an Associate Professor of Immunology at the University of Barcelona since September 2009.
Coordination of WP2 and WP3 tasks of ProDigest. This includes the implementation of a SHIME technology platform under IBD conditions and the use of the Host-Microbe-Interaction (HMI) module to analyse the impact of the gut environment on epithelial cells and mucus penetration.
Dr. ir. Pieter Van den Abbeele performed his PhD between 2007 and 2011 at the Laboratory of Microbial Ecology and Technology (LabMET, Ghent University), studying the effects of prebiotic compounds on the human gut microbiota with a focus on the investigation of mucosal gut microbes as potential guardians for human health. During this PhD research, unique in vitro models were developed and validated in order to allow the study of this largely unknown community of gut wall-associated microbes with high potential to affect health.
After performing postdoctoral research at Ghent University between 2011 and 2013, dr. Van den Abbeele joined ProDigest bvba, which is a spin-off company that commercialized the various in vitro models developed at LabMET. After working as a senior scientist on a European project of which ProDigest was the coordinator, dr. Van den Abbeele was appointed as ‘contract research and technology director’.
Scienseed is in charge of maximising the impact of the project through the development and execution of a comprehensive communication and outreach strategy. With its multidisciplinary team of scientists,creative artists and communicators Scienseed will bring the science of New Deal closer to the public as well as to relevant stakeholders from the clinic, pharma and regulatory fields.
Dr. Estela Cepeda graduated in Biology at Universidad Complutense in Madrid with a double major in Medical Biology and Biotechnology. She holds a PhD in Genetics and has wide research experience, which she carried out at the Cluster of Excellence in Cellular Stress Responses in Aging-associated Diseases (CECAD) from the University of Cologne (Germany). She is an expert in digital branding, marketing and project management and has ample experience in the development, management and execution of communication strategies in H2020 projects.
Our activities range from creating a visual identity for a project, creating the right communication materials – cleverly targeted to reach the designated audiences – designing and regularly updating the project’s website, handling press relations, developing a social media strategy to best suit the project needs and measuring research outcomes impact.
Ms. Caroline Estephan is Work Package leader for communication and dissemination activities, managing her team, partners and contractors to provide the project the best communication strategy as well as a smooth implementation for maximum project impact.
She is educated in marketing and communications (Novancia Business School Paris) with a strong interest in research and innovation. She has gained experience in various specialties ranging from marketing, internal communications, business development in both small start-ups or banking companies (Société Générale). She has joined Sparks & Co in 2015 to become Project Manager and is now WP leader of three Horizon 2020 projects in health research.
Staff members, specialists in immunology, inflammatory diseases or in therapy based on kinase inhibitors, will contribute to works of this project. Their expertise in the monitoring of the immune and inflammatory responses to evaluate the efficacy of the anti- inflammatory nano formulations produced by partners.
Amatsigroup will be responsible for the formulation of the nanoparticles and will provide a solution for colon delivery of the nanoparticles.
George Dakwar (1987) studied for the degree of “Bachelor of Science” in Chemistry and Life Sciences at the Hebrew University of Jerusalem (Israel). He then continued for a degree of “Master of Medical Sciences” specializing in Pharmacology at Ben-Gurion University of the Negev (Israel), where he graduated with cum laude. In July 2012, he received an award for his excellent achievements in Biomedical Research at the Ben-Gurion University of the Negev. In October 2012, he joined the Ghent Research Group on Nanomedicines (Ghent University, Belgium) and started a Ph.D. project under the supervision Prof. Katrien Remaut and Prof. Stefaan De Smedt. During his doctoral thesis, he focused on the development of lipid nanoparticles for siRNA delivery for intraperitoneal therapy of peritoneal carcinomatosis. In December 2016, he joined AmatsiGroup as a senior scientist at the department of biopharmaceuticals.
The main objective of Mayoly is to establish the future Clinical Development Plan of new siRNA-based nanotherapeutics. The aim is to ensure that sufficient information and evidence is generated to support the regulatory approval and initiation of a Phase 1 Clinical Study using the identified candidate from the programme for the treatment of IBD.
Chantal BURELOUT was initially trained as a pharmacist (Paris XI university- School of Pharmacy) and then obtained a master’s degreein Biochemistry (Faculty of Sciences at Orsay, Paris XI University). She was involved in immunopharmacology of inflammation and basophil cellular biology (Inserm U200, Paris) and was then employed as a pharmacist and a medical biologist in coprology and immunochemistry (Hôpital Pitié-Salpêtrière, Paris).
She later graduated as a PhD in Immunology—Microbiology (Laval University School of Medicine in Québec, Canada) where she worked on neutrophil intracellular signaling during the inflammatory reaction (chemoattractant and PGE2 signaling pathways, urate crystals signaling). As a post-doctoral fellow at the CEA (Atomic Energy Commission in Fontenay-aux-Roses, France), she managed a research project on the humoral response during the HIV /SIV primo-infection in men and macaque monkeys, and more particularly on the role of the cytokine BAFF in the B cell dyfunctions observed during the early phase of HIV/SIV infection. She joined Mayoly Spindler as a Drug Safety Officer in Jan. 2012.
Creation of a Clinical Development Plan for the product, co-ordinating the contact with the European Medicines Agency in the EU and the Food and Drug Administration in the USA in order to arrange a Scientific Advice Meeting and Pre-IND Meeting respectively with them, drafting the documentation to facilitate these meetings, responding to the feedback from these meetings and amending the development plans accordingly.
Professor Alan Boyd began his 30 years’ pharmaceutical career with Glaxo Group Research Ltd. From 1988 he led ICI’s cardiovascular medical research team, later assuming the role of Director of Clinical and Medical Affairs at ICI Pharma, Canada. In 1999, after four years as Head of Medical Research for Zeneca Pharmaceuticals, he became Director of Research and Development for Ark Therapeutics Ltd where he was responsible for delivering the majority of key development milestones that have shaped the company.
In April 2005, he left to set up Boyd Consultants. The focus of which is to aid and support early stage life-science based companies of the sort of which Ark had its origins. His clients now include many companies in Europe, North America and Japan who are devoted to the development of medical drug products, devices and in vitro devices.